Preoperative chemo-CIRT in Re/BRe pancreatic cancer: Insights from a multicenter prospective phase II clinical study (NCT03822936)
Tumori Journal · 2024
DOI: 10.1177/03008916241291341 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Tumori Journal, 2024. Verfasst von Amelia Barcellini und 14 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Unit, Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Purpose
There is debate about the optimal management of borderline resectable (bRe) and resectable (Re) pancreatic ductal adenocarcinoma (PDAC). Both preclinical and clinical evidence showed that carbon ion radiotherapy (CIRT) produces superior control on radioresistant histologies compared to conventional photon beam radiotherapy (RT). However, so far there is a lack of data concerning the integration of CIRT in a multimodal approach with chemotherapy and surgery for bRe/Re.
Methods
We recently presented the first analysis of a multicenter prospective phase II clinical study aimed at assessing the feasibility and effectiveness of a neoadjuvant chemotherapy + short course of CIRT followed by surgery and adjuvant chemotherapy in the management of bRe/Re PDAC. The study was terminated early due to low patient enrollment.Herein, we reported a post-hoc analysis focusing on toxicity, dosimetry and translational assessment.
Results
In our experience, CIRT can be integrated into a multimodal treatment strategy for bRe/Re PDAC, alongside chemotherapy and surgery. A case of fatal liver failure occurring three months post-surgery has been documented, likely related to the combination approach. Although the treatment plans were satisfactory according to the Local Effect Model (LEM) model, recalculations using the modified Microdosimetric Kinetic Model (mMKM) revealed suboptimal target coverage. Additionally, we observed an increased expression of PD-L1 following CIRT.
Conclusions
This multimodal approach was well tolerated; however, clinicians should carefully monitor for vascular disorders during follow-up and further investigate surgical techniques after CIRT. The increased PD-L1 expression supports the immunogenic effects of particle therapy and lays the groundwork for future studies. To enhance the therapeutic ratio of CIRT treatments, integrating LET-d based objectives into the plan optimization process should be considered. Trial Registration Number: ClinicalTrials.gov Identifier: NCT03822936
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Radiation Oncology Unit, Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy.
- Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
- Medical Physics Unit, Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy.
- Department of Molecular Medicine, Unit of Anatomic Pathology, University of Pavia, Pavia, Italy.
- Unit of Anatomic Pathology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
- Department of Radiation Oncology, MedAustron Ion Therapy Center, Wiener Neustadt, Austria.
ORCID-Profile: Amelia Barcellini, Alessandro Vai, Ester Orlandi
Zitieren
APA
Barcellini, A., Molinelli, S., Vanoli, A., Vitolo, V., Fossati, P., Vai, A., Pagani, A., Inzani, F., Pecorilla, M., Butturini, G., Klersy, C., Preda, L., Facoetti, A., Valvo, F., & Orlandi, E. (2024). Preoperative chemo-CIRT in Re/BRe pancreatic cancer: Insights from a multicenter prospective phase II clinical study (NCT03822936). Tumori Journal. https://doi.org/10.1177/03008916241291341
Vancouver
Barcellini A, Molinelli S, Vanoli A, Vitolo V, Fossati P, Vai A, et al. Preoperative chemo-CIRT in Re/BRe pancreatic cancer: Insights from a multicenter prospective phase II clinical study (NCT03822936). Tumori Journal. 2024. doi:10.1177/03008916241291341
BibTeX
@article{Barcellini2024,
author = {Barcellini, Amelia and Molinelli, Silvia and Vanoli, Alessandro and Vitolo, Viviana and Fossati, Piero and Vai, Alessandro and Pagani, Anna and Inzani, Frediano and Pecorilla, Mattia and Butturini, Giovanni and Klersy, Catherine and Preda, Lorenzo and Facoetti, Angelica and Valvo, Francesca and Orlandi, Ester},
title = {Preoperative chemo-CIRT in Re/BRe pancreatic cancer: Insights from a multicenter prospective phase II clinical study (NCT03822936)},
journal = {Tumori Journal},
year = {2024},
doi = {10.1177/03008916241291341}
}
EUVIMED